🇺🇸 FDA
Patent

US 9828432

Cancer treatment and monitoring methods using OX40 agonists

granted A61KA61K2039/505A61K2039/6031

Quick answer

US patent 9828432 (Cancer treatment and monitoring methods using OX40 agonists) held by Providence Health & Services—Oregon expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Providence Health & Services—Oregon
Grant date
Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/6031, A61P, A61P35/00